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Summary Investigation of transitional cell carcinoma of the urinary bladder (TCC) patients classified by recurrence and/or progression has
demonstrated that loss of chromosome 9, as detected by FISH analysis of the pericentromeric classical satellite marker at 9q12, occurs early.
A total of 105 TCCs from 53 patients were analysed in situ by two independent observers for loss of chromosome 9 using quantitative
fluorescence in situ hybridization (FISH). All 53 primary tumours were evaluated for chromosomes 9, 7 and 17. Normal ranges for
chromosomal copy number were defined for normal skin epidermis and bladder epithelium. Values for chromosome 9 copy number outwith
the range 1.51-2.10 (mean ± 3 x s.d. of normal values) were significantly abnormal. Twenty-five TCCs were detected with consistent
monosomic scores. Of 89 TCCs, in which multiple tumour areas were analysed, 85 tumours (96%) demonstrated the same chromosome 9
copy number in all areas (2-6) analysed; only three tumours demonstrated heterogeneity for this locus. A total of 36% (12 out of 33) of
patients with subsequent disease recurrence demonstrated loss of chromosome 9 in their primary and all subsequent TCCs analysed. Only
a single patient (n = 20) with non-recurrent TCC showed loss of chromosome 9 (P= 0.0085). Of 53 primary tumours, eight showed significant
elevation of chromosome 17. Of these patients, six demonstrated elevation in chromosome 7 copy number. No abnormalities were observed
in non-recurrent patients. This study describes rapid quantitation of chromosomal copy number by FISH using a pericentromeric probe for
chromosome 9 in TCC of the urinary bladder. Routinely fixed and processed material was evaluated without disaggregation. Strict quality
control of FISH demonstrated that this technique was reproducible in a clinical environment and could be used to detect genetic changes
relevant to patient outcome. It is proposed that loss of chromosome 9 from primary TCC of the urinary bladder identified patients at high risk
of recurrence and possible progression.
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Transitional cell carcinoma of the urinary bladder (TCC) is the
fourth commonest cancer of men in the UK, with a sex ratio of3:1
(M/F) and increasing mortality and incidence (Anon, 1984; 1987).
Patients with superficial TCC have a better prognosis (5-year
survival 95%) than those with detrusor muscle invasion (35% 5-
year survival; Anon, 1984; 1987). Low-stage and grade tumours
represent 70% of primary TCCs, but frequent recurrence and risk
ofdisease progression at recurrence mandate careful monitoring of
such patients (McCredie, 1994; Ozen, 1994). Current management
is by cystoscopy 3, 6 and 12 months after each recurrence, and
annually thereafter (McCredie, 1994; Ozen, 1994). No predictive
marker of recurrence or progression has yet been identified using
conventional pathological staging and grading (UICC, 1978) or by
molecular and biochemical techniques.
Investigations of TCC tumours have identified potentially
important loci for genetic abnormality (Sandberg, 1992; Miyao et
al, 1993; Matsuyama et al, 1994; Sauter et al, 1994; Kallioniemi et
al, 1995). Losses on many chromosomes, including 17, 11, 9, 8, 5
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and 3 have been associated with high stage and grade, and links
have been implied to poor disease outcome (Sandberg, 1992;
Miyao et al, 1993; Matsuyama et al, 1994; Sauter et al, 1994;
Kallioniemi et al, 1995).
Loss ofchromosome 9 loci is the most frequently observed and
studied genetic event in TCC. To date, three discrete loci for
genetic loss have been identified on this one chromosome. After
observation that ABO blood group antigens were frequently lost in
bladder cancer it was shown that loss of the distal long arm of
chromosome 9 (9q34) was also frequent (22-60%). A distinct
region of loss has been identified at 9q22 (Orlow et al, 1994;
Habuchi et al, 1995). Recently, interest has centred on loss on
chromosome 9p2l in TCC. The identification of a tumour-
suppresser gene (MTS1, p16) at this locus and the high frequency
of its loss in TCC (Linnenbach et al, 1993; Devlin et al, 1994;
Keen and Knowles, 1994) confirm the importance of 9p2l as the
site of an early bladder cancer event. Between 28% and 60% of
tumours have been shown to lack copies of all chromosome 9 loci
(Keen and Knowles, 1994; Orlow et al, 1994; Habuchi et al, 1995;
Sauter et al, 1995) tested.
In most studies comparisons oftumourgenetic events have been
without reference to the patient's clinical outcome. A major diag-
nostic challenge in TCC is early identification ofpatients at risk of
recurrence or progression. This study suggests that early events in
tumorigenesis can provide clues to patient outcome.
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Table 1 Patient demographic information
NR (n=20) RNP (n = 21) RP (n = 12)
Age at diagnosis (mean + s.d.) 67.0 ± 8.3 68.5 ± 12.1 65.1 ± 13.2
Sex M/F 16:4 15:6 8:4
Follow-up years (mean + s.d.) 5.1 ±3.4 5.2 ± 4.2 4.3+ 3.8
Number of tumours per patient (mean + s.d.) 1 6.4 ± 4.2 6.8 ± 2.6
Number of cystoscopies (mean + s.d.) 8.0 ± 4.3 10.0 + 6.3 9.5 ± 7.7
(range 1-18) (range 2-22) (range 3-30)
Stage
pTa 13 (65%) 16 (76%) 6 (50%)
pTl 6 (30%) 5 (24%) 6 (50%)
pT2 1 (5%) - -
pT2+ - - -
Grade
1 8 (40%) 12 (58%) 4 (33%)
2 10 (50%) 8 (37%) 3 (25%)
3 2 (10%) 1 (5%) 5 (42%)
Outcome (number dead from bladder cancer) 0 0 5
NR, non-recurrent; RNP, recurrent non-progressive; RP, recurrent progressive. Age, mean age (± standard deviation) of patients in each group at first diagnosis.
Follow-up, mean follow-up (years + s.d.). Tumours, mean number of tumours per patient. TCC deaths, number of patients/group who died from TCC. pTa/pT1,
distribution of stage, grade (G1-G3) for primary tumour events from each patient.
MATERIALS AND METHODS
Three patient groups were studied. Patients with a solitary episode
of superficial (pTa-pT1) TCC who showed no subsequent disease
over 3 or more years of follow-up (non-recurrent group, NR).
Patients with superficial TCC and subsequent, often repeated,
recurrence of superficial disease but without progression to
detrusor muscle invasion or metastasis (recurrent non-progressive
group, RNP). Finally, patients presenting with superficial papillary
TCC who subsequently progressed to invasion of the bladder wall
or to metastasis (pT2-4; recurrent progressive group, RP).
Twenty NR, 21 RNP and 12 RP patients were identified for this
study. All patients had their primary superifical tumours analysed.
In 12 RNP and eight RP patients subsequent tumour events were
also analysed.
Patients were selected for availability of TCC tissue from all
primary and recurrent carcinomas; patients with diathermy
without biopsy of any events before primary, recurrent TCC or the
first invasive event (pT2-4), or presenting with primary invasive
TCC (pT2-4) or with inadequate referral, or when material was
inadequate for sampling were excluded. No significant differences
in patient age (P = 0.234), male-female ratio (P = 0.41), mean
follow-up (P = 0.279), number of cystoscopies (P = 0.77),
(P = 0.31) or grade (P = 0.35) at presentation were observed
between different patient groups (Table 1).
Fluorescence in situ hybridization (FISH)
Serial 6-gm skin sections and subsequently normal bladder sections
were used as positive controls within each experimental run. FISH
was performed as described previously (Murphy et al, 1995).
Essentially, 6 jim-sections on silane-treated slides (Sigma, UK)
were dewaxed and rehydrated immediately before use. Pepsin
digestion was performed at 37°C for 15-60 min. Sections were
washed and post-fixed in Streck tissue fixative (Alphalabs,
Cambridge, UK), dehydrated and air dried. Chromosome 9 classical
satellite probe (9q12, Appligene Oncor UK) or a combination of
chromosome 7 and 17 alpha satellite probes (Appligene Oncor UK)
diluted in hybridization mix (50% formamide, 2 x sodium saline
citrate (SSC), 0.5% salmon sperm DNA, 10% dextran sulphate, all
from Sigma) were applied and sections denatured at 72°C for 5 min
and incubated overnight at 37°C. After post-hybridization washes,
signal was detected using sheep anti-digoxigenin (Boehringer, UK),
FITC anti-sheep (Stratech, UK) for chromosome 9, and FITC
avidin/biotinylated goat anti-avidin (both Vector) with rabbit anti-
digoxigenin/CY3 labelled donkey anti-rabbit (both from Jackson)
for chromosomes 7 and 17. Slides were mounted in Vectashield
(Vector, UK) mountant containing DAPI (30 ,ug ml', Sigma, UK)
and sealed. Signals were visualized using a DMLB Microscope
100-W mercury lamp (Leica, UK). Image analysis of nuclear size
confirmed that variations between tumours and skin controls were
non-significant both statistically and in terms of impact on nuclear
truncation (see Phalplatz et al, 1995).
Scoring procedure
All control and carcinoma samples were scored 'blind' and inde-
pendently by two observers, in each area/section epithelial cell
nuclei were identified and the number of observed signals, repre-
senting hybridization of the DNA probe (0, 1, 2, 3, etc.) per
nucleus, recorded using a multichannel counter for 200 nuclei per
section (Figure 1). Analysis of results demonstrated that both the
monosomic cell population (MCP) and the mean chromosome
copy number/nucleus (MCCN) ratio were equivalent measures of
monosomy 9 (data not shown). For each area of tissue, values
were calculated for both observers, and the interobserver mean
calculated as the final value for the section in question.
Multiple areas ofcarcinoma (range 1-6, median 3) were scored
for each carcinoma and analysed as described above to ensure
scoring results were consistent in all tumour samples. Tumour
areas were scored by each observer repeatedly (two to four times)
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Figure 1 Illustrative example of scoring histogram from four tumours, Scoring data from two observers for four tumour areas. Number of cells scored (vertical
axis) with 0, 1, 2 or 3 chromosome signals (horizontal axis). F2, K1 represent two monosomic tumours for chromosome 9; FI[I, MI two disomic tumours for
chromosome 9. Monosomic tumours show predominantly cells with single copies, whereas disomic tumours show predominantly two copies of chromosome 9
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D
Figure 2 (A) Photomicrograph of tumour biopsy showing areas of tumour selected for analysis. (B) Fluorescence photomicrograph of normal skin epithelium.
Note disomic signal pattern throughout. (C) Fluorescence photomicrograph of TCC bladder epithelium with no loss of chromosome 9. Note disomic signal
pattern throughout. (D) Fluorescence photomicrograph of TCC bladder epithelium with loss of chromosome 9. Note loss of signals throughout
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on separate occasions to evaluate intraobserver variation.
Interobserver variation between areas was calculated using mean
values from observer A and observer B for each area of tumour
scored. Overall interobserver variation was calculated as the mean
variation for all areas evaluated.
Statistics
Differences between multiple groups were analysed using
ANOVA (in the case of parameters such as age, length of follow-
up, etc.) or chi-squared tests (for stage, grade, sex ratios, etc.) as
appropriate. Survival was analysed using Kaplan-Meier analysis
with the log-rank test.
RESULTS
Patients
There were no significant differences in any measured parameters
between patients at recruitment into the different study groups. By
definition, the progress of disease in each of the patient groups
showed marked differences. Strikingly, numbers of cystoscopies
per patient were not significantly different between patients with
NR and recurrent disease (Table 1). The probability ofdying from
any cause was significantly greater in recurrent patients (P =
0.0402). The probability of dying from bladder cancer (P =
0.0032) was significantly higher for RP patients as all TCC-related
deaths were in progressed patients.
Fluorescence in situ hybridization
Nuclear diameters for control sections were 7.4 ptm ± 12.5%, the
range for tumour median diameters was 6.68-9.04,m.
Calculations based on the method ofPhalplatz et al (1995) suggest
that the maximum error, relating to a hypothetical change in
nuclear size between control samples and tumours would be
10.12%, well within the detection criteria of this technique.
However, this result would suggest that for detection of polyploi-
dies above n = 6 a potential for type II sampling error between the
control and the tumour samples exists. Samples analysed showed
clear hybridization at two loci in the majority of nuclei from skin
sections (Figure 2B). Areas of tumour from patients were either
uniformly similar to skin in appearance (Figure 2C) or showed a
high proportion of signal loss (Figure 2D).
The results of analysis of replicate scoring of either 24 sections
(observer A) or 35 sections (observer B) demonstrated that the
mean chromosomal copy number showed greater consistency
of reporting with mean intraobserver variation of 11.91%
(8.01-15.81%) than the percentage monosomic cell population. For
both chromosomes normal ranges were defined as the mean chro-
mosomal copy number ± 3 x s.d. for values obtained for control
tissues. For chromosome 9 the normal range was 1.51-2.10 and for
chromosomes 7 and 17 the normal range was 1.37-1.85; this
reflects the lower hybridization efficiency of these probes. MCCN
values obtained for tumour samples incorporate a 4.00% or 6.00%
(chromosomes 9 and 7 or 17 respectively) observer error that was
taken into account when defining abnormalities.
In all, 135 carcinoma areas were scored by both observers,
mean interobserver variation for MCP was 15.02% (median
II1.9%, maximum 59.42%), whereas the mean interobserver vari-
ation for chromosomal copy number was 4.00% (median 3.57%,
maximum 15.58%). In the majority of cases (96.0%) tissue chro-
mosome 9 copy numbers were consistent in all areas of tumour
evaluated; in only three tumours was heterogeneity of copy
number at this locus identified. In one RNP patient the first recur-
rence demonstrated one tumour area with a mean chromosomal
copy number of 0.9 for chromosome 9, the final recurrence from
this patient showed consistent monosomy throughout. Secondly, in
one RP patient, the primary tumour was monosomic in two out of
four areas, with a mean chromosomal copy number of 1.02. Both
these patients were clearly classified as monosomic. Finally, in
one NR patient a single area out of four scored showed a mean
chromosomal copy number of 1.37, with other areas showing a
mean copy number of 1.75. This result falls outwith the range
observed for both monosomic and disomic patients, such that this
area cannot be truly classified as either monosomic or disomic and
has been excluded from analysis.
Chromosome 9 monosomic tumours/patients
Of 53 primary tumours analysed for chromosome 9 copy number,
13 were monosomic and 40 disomic for chromosome 9 copy
number. Overall, monosomy for this locus could be clearly
demonstrated in 1 out of 20 NR (5%) and 12 out of 32 (36%) of
primary recurrent (either RNP or RP) tumours (P = 0.0085; Figure
3). Ofall patients, 1 out of20 NR and 13 out of32 (41%) ofrecur-
rent patients demonstrated monosomy during the course offollow-
up (P = 0.0048). No difference in the rate of monosomy of
tumours was apparent between RNP or RP patients.
Monosomy for the chromosome 9 classical satellite detected in
the primary tumour from a patient was clearly associated with
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Figure 3 Mean chromosomal copy number (vertical axis) in primary
tumours from patients with non-recurrent (NR), recurrent non-progressive
(RNP) and recurrent progressive (RP) disease. One out of 20 non-recurrent
tumours and 12 out of 33 recurrent (RNP + RP) patients showed monosomy
for chromosome 9 in their primary tumours
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disease recurrence (P = 0.0085) and also with monosomy of all
subsequent tumours. No significant difference in the rates of
monosomy of primary tumours was observed between RNP and
RP patients (Figure 2).
Of 104 TCC analysed, 28 (28%) were monosomic throughout.
Of superficial TCCs (pTa-pT1) 24.6% were monosomic vs 44.4%
of advanced (pT2 + n = 9) TCCs. When segregated by grade,
28.6% of GI, 41.7% of G2 and 26.7% of G3 tumours were mono-
somic, in that order. No relationship between monosomy and
tumour stage or grade was identified. Of the 28 monosomic
tumours, two represented the last known event from two separate
RP patients (2 out of 12, 16.7%), whereas the remaining 26
tumours represented all tumour events analysed, including the
primary TCC, from a further 12 patients (seven RNP patients
(33%) and five RP patients (42%) (Figure 4)) . A single NR patient
showed monosomy.
Chromosome 7 and 17
A total of 53 primary tumours were scored for chromosome 7 and
17 copy number. All 20 NR patients showed normal copy numbers
for chromosomes 7 and 17 (chromosome 7 mean 1.73, range
1.61-1.87, 17 mean 1.71, range 1.51-1.91). Of 33 primary
tumours from recurrent/RP patients 25 exhibited normal copy
numbers for chromosome 17. The remaining eight tumours (24%)
showed significant elevations in MSNR (range 2.01-2.66); of
these, six showed elevations in MSNR for chromosome 7 (range
1.98-2.71). No significant relationship between abnormalities of
chromosome 7 or 17 and stage (either pTa or pT1) or grade was
observed. No relationship between monosomy chromosome 9 and
polysomy 17 was observed. A modestly significant link between
polysomy 7 and 17 and recurrence could be established (P = 0.04,
chromosome 17, P = 0.015 chromosome 7).
DISCUSSION
Analysis ofchromosome 9 copy number using the pericentromeric
classical satellite at 9q12 has been widely used in studies of TCC
ofthe bladder (Matsuyama et al, 1994; Orlow et al, 1994; Sauter et
al, 1995). By identifying patients with known disease outcome,
this study demonstrates that loss of this locus, and presumably of
the whole chromosome, implies elevated risk of recurrent TCC.
The consistency ofthis loss and its early occurrence may provide a
predictive marker of disease outcome in these patients.
Most studies of molecular events in TCC have evaluated rela-
tionships between tumour stage and grade. The current investiga-
tion has investigated genetic events within TCC and disease
outcome. To achieve this aim, patients were selected and grouped
by outcome as defined above. Three patient groups were evalu-
ated: those with single superficial (pTa/pTl) TCC (NR patients),
those whose TCC recurred without progression (RNP patients) and
those who progressed to invasive TCC at recurrence (RP patients).
This patient-based evaluation focuses on molecular mechanisms
underlying these clinically distinct disease processes that can be
exploited for diagnosis or therapy.
Patients in the three groups were similar in age, sex ratio and
follow-up, including numbers of cystoscopies. Analysis of the
primary TCC from these patients showed a relationship between
disease outcome and high grade (GI vs G2 + 3) but not stage
(Table 1).
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Figure 4 Chromosomal copy number for chromosome 9 in recurrent
tumours. Mean chromosomal copy number (vertical axis) in recurrent
tumours from representative patients from both RNP and RP groups.
Tumours analysed were primary, first identified superficial TCC for all
patients; 1st recurrence, first recurrence in all patients (also superficial);
preinvasion, last identified tumour for RNP and last non-invasive (pTa/pTl)
tumour for RP patients; post-invasion, for RP patients only, first diagnosed
invasive tumour (pT2+). A, A, two RNP patients (BLA32 and BLA33) with
monosomy 9 in all tumours analysed; 0, 0, two RNP patients (BLA92 and
BLA145) with disomy 9 in all tumours analysed; *, C], two RP patients with
Monosomy 9 in all tumours analysed (BLA45 and BLA135); V, V, two RP
with disomy 9 in all tumours analysed (BLA3 and BLA12), *, O, 2 RNP
patients with disomy 9 in their primary tumours who subsequently
demonstrated monosomy 9 (BLA40 and BLA78)
The FISH method used to quantify chromosomal copy number
in situ has been critically evaluated. Scoring was performed
independently by two observers and variation between observers
shown to be consistently low for the MCCN (8-15%). Essentially,
the parameters investigated are interchangeable (Figure 1),
although MCCN is consistently less variable than MCP.
An interesting finding was the consistency of genetic alter-
ations, not only within tumour samples taken at a single time point
but also across TCCs from the same patients many years apart.
This contrasts with high rates of tumour heterogeneity reported in
other studies for different loci. Although some loci may show
spatial and temporal heterogeneity in tumour cells, this is a signif-
icant finding in TCC for this chromosome 9 locus. Other loci show
heterogeneity in TCC (Schapers et al, 1993), but this is not a
uniform finding (Oliver et al, 1992). It appears that markers of
tumour behaviour may exist that are not complicated by problems
of intratumour heterogeneity.
In addition to the observation that loss of chromosome 9 is
consistent in multiple samples of single TCC tumours, it is clear
that such loss occurs early and persists when multiple TCCs from
single patients are evaluated. Of the 20 patients evaluated over
time at this locus, only two showed a change in chromosomal copy
number during the course of their disease, in both this was a later
event. This demonstrates that although early loss ofchromosome 9
is usual in TCC, later changes cannot be ruled out.
Arguably the finding that genetic changes in primary TCC may
predict those in subsequent tumours is of greatest diagnostic
interest. We have previously identified c-erbB-2 gene amplifica-
tion in TCC as a marker ofinvasion and poor survival (Underwood
et al, 1995), but c-erbB-2 amplification failed to predict invasion
early enough to allow for a modification in patient management. In
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this context, the consistency of chromosome 9 losses between
primary tumours and recurrences more than 5 years later suggests
that diagnostic markers of value may exist. We have investigated
the relationship between monosomy 9 and chromosomes 7 and 17,
solely in primary tumours, to determine whether the lesion on
chromosome 9 is specific. No alterations in copy number for chro-
mosomes 7 and 17 tested was observed in NR patients. Lower than
expected frequencies of polysomy 7 and 17 were observed in the
primary tumours from recurrent patients (8 out of 33; 24%).
Abnormalities in chromosomes 7 and 17 were confined in this
study to patients destined to recur, and there was a modest link
between polysomy 7 or 17 and recurrences (P = 0.04 and 0.02
respectively). Other studies have identified higher rates of
polysomy for 7 and 17 in bladder tumours; our finding may
suggest, as is highlighted elsewhere, that aberrations in these
chromosomes occur later in the disease process (Sandberg, 1992;
Schapers et al, 1993; Matsuyama et al, 1994; Sauter et al, 1995;
Resnikoff et al, 1996). We have selectively studied primary super-
ficial tumours in this cohort rather than recurrent and progressive
(pT2 +) tumours in previous reports. There is therefore a marked
difference in our tumour cohort from those in previous studies, and
this difference may explain differences in rates ofaneusomy 7 and
17 observed.
The relationship between disease recurrence and chromosome 9
may suggest the existence of a 'recurrence'-related gene on this
chromosome, the identification of which may in future provide a
therapeutic target. The specific loci that have been previously
identified as sites ofloss in TCC that are candidates for this 'recur-
rence' gene remain to be evaluated. It may be that such a gene is
not in itself related to recurrence but rather in a manner analagous
to that for p53, may allow or be associated with further genetic
changes that result in recurrence.
This study identifies chromosome 9 loss as a possible
predictive marker for disease recurrence in TCC patients.
Analysis of patient outcome in this multistage disease shows
a relationship between loss of chromosome 9, measured by
FISH of the 9q12 classical satellite, in primary tumours ofpatients
and disease recurrence. Wider prospective or retrospective
analysis is required to confirm the usefulness of this marker for
early identification of patients with superficial TCC at risk of
recurrence and therefore progression. This study validates the
search for molecular markers of disease outcome in TCC.
Subchromosomal studies of chromosome 9 may localize a poten-
tial 'recurrence' gene and increase the range of patients for whom
this test may be of value.
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